# US 2021/0276964 A1 · Compositions and methods for treating cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276964 A1
- Document ID: US20210276964A1
- Status: Published application
- Kind: A1
- Application number: 17/066,397
- Filed: 2020-10-08
- Published: 2021-09-09
- Earliest claimed: 2014-06-12
- Assignees: Cedars-Sinai Medical Center
- Applicants: Cedars-Sinai Medical Center
- Inventors: Mouad Edderkaoui; Ramachandran Murali; Stephen Pandol
- Web page: https://patentgrep.com/patent/US20210276964A1

## CPC

- C07D 285/08: 1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/4245: Oxadiazoles
- A61K 31/433: Thidiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 271/10: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D 271/107: with two aryl or substituted aryl radicals attached in positions 2 and 5
- C07D 271/113: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

## Claims

### Claim at position 1

-107. (canceled)

### Claim 108

A method of treating a cancer in a human subject, comprising:
administering a therapeutically effective amount of a compound of Formula (IV):
wherein:
L1 and L2 are independently a linker;
R1 is an aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted;
R2 is hydrogen, lower alkyl, cyclyl, heterocyclyl, aryl, or heteroaryl, each of which can be optionally substituted;
R3 is absent or an aromatic moiety, which can be optionally substituted;
p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and
wherein -L1R1 is linked to one nitrogen of the thiadiazolidine ring and —(CH2)p—R3-L2-C(O)NHOR2 is linked to the other nitrogen of the thiadiazolidine ring.

### Claim 109 (depends on 108)

The method of claim 108, wherein the compound has the structure of Formula (VI):

### Claim 110 (depends on 109)

The method of claim 109, wherein the compound has the structure of Formula (I):
wherein:
X is a linker group; and
Y is absent or an aromatic substituent.

### Claim 111 (depends on 3)

The method of claim 3, wherein the compound has the structure of Formula (I-1):
wherein n is an integer from 1 to 12.

### Claim 112 (depends on 108)

The method of claim 108, wherein the compound is:

### Claim 113 (depends on 2)

The method of claim 2, wherein the compound has the structure of Formula (VI):

### Claim 114 (depends on 6)

The method of claim 6, wherein the compound has the structure of Formula (II):
wherein:
X is a linker group, and R is -L1R1.

### Claim 115 (depends on 7)

The method of claim 7, wherein the compound has the structure of Formula (II-1):

### Claim 116 (depends on 108)

The method of claim 108, wherein administering the therapeutically effective amount of the compound of Formula (IV) comprises administering a composition comprising the compound linked to a particle.

### Claim 117 (depends on 116)

The method of claim 116, wherein the particle is a magnetic particle.

### Claim 118 (depends on 116)

The method of claim 116, wherein the compound is linked to the particle via a linker comprising a cleavable linking group.

### Claim 119 (depends on 118)

The method of claim 118, wherein the cleavable linking group is cleavable by an enzyme.

### Claim 120 (depends on 119)

The method of claim 119, wherein the cleavable linking group is cleavable by an enzyme enriched in a cancer or tumor.

### Claim 121 (depends on 119)

The method of claim 119, wherein the cleavable linking group is cleavable by a peptidase enriched in a cancer or tumor.

### Claim 122 (depends on 119)

The method of claim 119, wherein the cleavable linking group is a cleavable substrate of Cathepsin G.

### Claim 123 (depends on 116)

The method of claim 116, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.

### Claim 124 (depends on 116)

The method of claim 116, wherein the composition is formulated for topical, intravascular, intravenous, intraarterial, intratumoral, intramuscular, subcutaneous, intraperitoneal, intranasal or oral administration.

### Claim 125 (depends on 116)

The method of claim 116, further comprising administering an anti-cancer therapeutic agent.

### Claim 126 (depends on 125)

The composition of claim 125, wherein the anti-cancer therapeutic agent is a chemotherapeutic agent.

### Claim 127 (depends on 108)

The method of claim 108, wherein the cancer is pancreatic cancer.
